Lipocine
LPCN
39 hedge funds and large institutions have $13M invested in Lipocine in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 8 closing their positions.
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
5% more funds holding
Funds holding: 37 → 39 (+2)
0.28% less ownership
Funds ownership: 1.33% → 1.05% (-0.28%)
30% less capital invested
Capital invested by funds: $18.6M → $13M (-$5.54M)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
53% less call options, than puts
Call options by funds: $566K | Put options by funds: $1.21M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
+$622K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$329K |
| 3 |
Morgan Stanley
New York
|
+$243K |
| 4 |
SIM
Spark Investment Management
New York
|
+$46.1K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$43.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$2.56M |
| 2 |
DAM
DLD Asset Management
New York
|
-$1.03M |
| 3 |
Renaissance Technologies
New York
|
-$908K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$559K |
| 5 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$397K |
LPCN Hedge Fund Activity: Q4 2017 in Review
39 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2017, worth a combined $13M — down 30% from $18.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LPCN positions and 8 closed out — a net gain of 2 holders — while 7 added to existing stakes and 14 trimmed.
The largest buyer was Carlson Capital, adding an estimated $622K. The largest seller was Royce & Associates, cutting an estimated $2.56M.
- 39 institutional investors held Lipocine (LPCN) as of Q4 2017, up from 37 in Q3 2017.
- Funds reported $13M of Lipocine stock for Q4 2017, down 30% quarter-over-quarter.
- 10 funds opened new Lipocine positions in Q4 2017 and 8 closed out, a net change of +2 holders.
- The largest Lipocine buyer in Q4 2017 was Carlson Capital, an estimated $622K added.
- The largest Lipocine seller in Q4 2017 was Royce & Associates, an estimated $2.56M sold.
Based on aggregated 13F filings for Q4 2017.